Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Istios Health is a regenerative medicine company focused on developing advanced synthetic scaffolds for soft tissue repair and chronic wound management. Spun out of the Kaplan Lab at Tufts University, the company utilizes a proprietary silk fibroin-based platform to create bio-resorbable templates that facilitate natural tissue regeneration. Their lead technology is designed to address the limitations of current biological skin substitutes, such as high costs, complex storage requirements, and inconsistent clinical outcomes. By providing a scalable and shelf-stable synthetic alternative, Istios Health aims to improve access to high-quality wound care for patients suffering from diabetic foot ulcers and venous leg ulcers. The company's platform optimizes the microenvironment to promote cellular infiltration and rapid vascularization, ultimately accelerating the healing process.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Istios Health.